

NFKB p65 Antibody HRP Conjugated

Catalog No: #C00285H

Orders: order@signalwayantibody.com

Support: tech@signalwayantibody.com

Description

Product Name	NFKB p65 Antibody HRP Conjugated
Host Species	Rabbit
Clonality	Polyclonal
Isotype	IgG
Purification	Purified by Protein A.
Applications	WB IHC-P IHC-F
Species Reactivity	Hu Ms Rt
Immunogen Description	KLH conjugated synthetic peptide aa 50-100 551 derived from human NFKBp65
Conjugates	HRP
Target Name	NFKB p65
Other Names	p65; NFKB3; Transcription factor p65; Nuclear factor NF-kappa-B p65 subunit; Nuclear factor of kappa light polypeptide gene enhancer in B-cells 3; RELA
Accession No.	Swiss-Prot#Q04206NCBI Gene ID5970
Uniprot	Q04206
GeneID	5970;
Excitation Emission	N A
Cell Localization	Cytoplasm
Concentration	1mg ml
Formulation	0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Storage	Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Application Details

WB=1:500-2000 IHC-P=1:50-200 IHC-F=1:50-200

Background

NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA p65, RELB, NFKB1 p15, NFKB1 p5, REL and NFKB2 p52 and the heterodimeric p65-p5 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p5 and p65-c-Rel complexes are transcriptional activators. The NF-kappa-B p65-p65 complex appears to be involved in invasin-mediated activation of IL-8 expression. The inhibitory effect of I-kappa-B upon NF-kappa-B the cytoplasm is exerted primarily through the interaction with p65. p65 shows a weak DNA-binding site which could contribute directly to DNA binding in the NF-kappa-B complex. Associates with chromatin at the NF-kappa-B promoter region via association with DDX1.

Note: This product is for in vitro research use only